MyoKardia (MYOK) IPO Opens 10% Higher

Today's IPO for MyoKardia (NASDAQ: MYOK) opened for trading at $11.08 after pricing 5,437,500 shares of common stock at a public offering price of $10.00 per share.

Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as lead book-running managers. Wells Fargo Securities is acting as book-running manager. Wedbush PacGrow is acting as co-manager.

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. MyoKardia’s most advanced product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM and is currently being evaluated in three Phase 1 clinical trials. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry, or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia believes that SHaRe, currently consisting of data from approximately 10,000 individuals, is the world’s largest registry of patients with heritable cardiomyopathies. MyoKardia’s purpose is to improve the lives of patients and families suffering from cardiovascular disease by creating targeted therapies that can change the course of their condition.

You May Also Be Interested In

• AMR Resources prices $250M IPO on Nasdaq at $10 per unit
• Standard Nuclear files for downsized IPO
• Crescent Biopharma raises $143.7M in public offering on Nasdaq